Granahan Investment Management Inc. MA lifted its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 483,800 shares of the biopharmaceutical company’s stock after purchasing an additional 24,599 shares during the quarter. Nektar Therapeutics accounts for about 1.0% of Granahan Investment Management Inc. MA’s investment portfolio, making the stock its 28th biggest holding. Granahan Investment Management Inc. MA owned 0.31% of Nektar Therapeutics worth $11,611,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. World Asset Management Inc raised its stake in shares of Nektar Therapeutics by 5.6% in the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 539 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Nektar Therapeutics by 14.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 692 shares during the last quarter. Arizona State Retirement System increased its position in Nektar Therapeutics by 1.0% during the second quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company’s stock valued at $1,582,000 after acquiring an additional 800 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in Nektar Therapeutics by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 929 shares during the last quarter. Finally, Amalgamated Bank increased its position in Nektar Therapeutics by 8.7% during the second quarter. Amalgamated Bank now owns 20,563 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 1,644 shares during the last quarter. Hedge funds and other institutional investors own 96.04% of the company’s stock.

Shares of Nektar Therapeutics (NASDAQ NKTR) opened at $53.97 on Monday. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 1 year low of $11.41 and a 1 year high of $55.42.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.16. The business had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The business’s quarterly revenue was up 321.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.32) earnings per share. research analysts anticipate that Nektar Therapeutics will post -0.75 EPS for the current fiscal year.

NKTR has been the subject of a number of research reports. BidaskClub upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Mizuho upped their price objective on Nektar Therapeutics from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 14th. Jefferies Group reiterated a “buy” rating and set a $35.00 price objective on shares of Nektar Therapeutics in a research report on Wednesday, November 8th. Canaccord Genuity upped their price objective on Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, November 13th. Finally, ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $35.58.

In other Nektar Therapeutics news, Director Christopher A. Kuebler sold 4,000 shares of the company’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $21.86, for a total value of $87,440.00. Following the completion of the sale, the director now owns 40,500 shares in the company, valued at $885,330. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO John Nicholson sold 15,910 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $37.78, for a total value of $601,079.80. Following the completion of the sale, the chief operating officer now owns 249,066 shares of the company’s stock, valued at approximately $9,409,713.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 858,094 shares of company stock valued at $22,868,634. Company insiders own 5.44% of the company’s stock.

WARNING: “Nektar Therapeutics (NKTR) Stake Lifted by Granahan Investment Management Inc. MA” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/11/nektar-therapeutics-nktr-stake-lifted-by-granahan-investment-management-inc-ma.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.